Trevi Therapeutics (TRVI) PT Raised to $16 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Roanna Ruiz raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $16.00 (from $13.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
